# Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine

> **NCT00946946** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 78 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Azathioprine
- **DRUG:** Mesalazine
- **DRUG:** Azathioprine placebo
- **DRUG:** Mesalazine placebo

## Key facts

- **NCT ID:** NCT00946946
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2007-05
- **Final completion:** 2009-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2012-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946946, "Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00946946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*